Disc Medicine, Inc.

NASDAQ:IRON

Biotechnology

Healthcare
$77.98 -0.03%

-$0.02 today

Market cap
$2.99B
Beta
2.10
P/E (TTM)
-11.2
EPS (TTM)
-$6.28
52W Low $40.00High $99.50

Volume 0.95M

Average 0.47M

IRON Purchases of Investments

Cash used to buy marketable securities and other investments.

Disc Medicine, Inc.NASDAQ: IRON

Purchases of Investments · Q3 FY2026 · quarter ended Sep 2026

Purchases of investments growth accelerates

Q3 FY2026 purchases of investments of $118.48M (cash outflow) rose 38.7% year over year, ahead of the +17.6% change in trailing-twelve-month purchases of investments. Sequentially, it rose 27.8% from the prior quarter.

Context

  • Purchases of investments increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +38.7% holds above the trailing-twelve-month pace of +17.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$118.48M+27.8% QoQ
Last fiscal yearDec 2025
-$849.59M+119.7% YoY
LTMSep 2026
-$663.25M+17.6% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+38.7%——
1 year+119.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(849.59M) USD
Year-over-year change
-119.7%

Purchases of Investments vs competitors

How IRON compares with its peers on the latest reported figures

  • IRON's LTM Sep 2026 purchases of investments of $663.25M is the largest of the 6 companies compared; the peer median is $252.5M.
  • Its year-over-year change of +17.6% is the 2nd highest of 4, against a peer median of -36.1%.
IRON Competitors Peer median
Purchases of Investments for IRON and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IRONDisc Medicine, Inc.LTM Sep 2026$663.25M +17.6%——
AGIOAgios Pharmaceuticals, Inc.LTM Mar 2026$615.04M -58.3%-14.6%931.2%
GERNGeron CorporationLTM Mar 2026$292.47M -36.1%+5.7%149.1%
COAGHemab Therapeutics Holdings, Inc. Common StockFY2025$252.5M ———
PTGXProtagonist Therapeutics, Inc.LTM Jun 2026$77.55M +111.7%+36.5%27.5%
DMRADamora Therapeutics, Inc.LTM Jun 2024$3.94M ———
Peer median (excluding IRON) $252.5M-36.1%+5.7%149.1%

Competitors are the stored peer set for IRON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(35.97M)(46.83M)(76.43M)(109.36M)(212.18M)
Depreciation & Amortization32K89K100K156K281K
Deferred Income Tax00000
Stock-Based Compensation507K2.09M5.53M16.82M34.34M
Change in Working Capital1.29M2.13M(2.95M)3.23M3.53M
Accounts Receivables00000
Inventory00000
Accounts Payables1.32M526K(3.74M)(4.68M)1.07M
Other Working Capital(29K)1.6M788K7.91M2.46M
Other Non-Cash Items6.61M272K290K(4.77M)(6.36M)
Operating Cash Flow(27.53M)(42.25M)(73.46M)(93.93M)(180.39M)
Capital Expenditures(68K)(151K)(89K)(505K)(933K)
Acquisitions (Net)00000
Purchases of Investments000(386.63M)(849.59M)
Sales of Investments00094.8M456.22M
Other Investing Activities00000
Investing Cash Flow(68K)(151K)(89K)(292.33M)(394.3M)
Debt Repayment(4.58M)0028.99M0
Common Stock Issued68K53.5M199.08M187.3M472.83M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities4.58M95.48M40.3M2.02M578K
Financing Cash Flow89.93M148.98M239.38M218.31M473.41M
Effect of Forex Changes00000
Net Change in Cash62.33M106.58M165.83M(167.94M)(101.29M)
Free Cash Flow(27.6M)(42.4M)(73.55M)(94.43M)(181.33M)

Disc Medicine, Inc.

NASDAQ:IRON

Intrinsic Alpha fair value

Locked

Current Price

$77.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.